2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2177

Sarcopenia and the Likelihood of Incident Knee Osteoarthritis and Knee Pain Among Older Adults in the Health ABC Study
Abstract Number: 1657

Sarcopenia in Systemic Sclerosis
Abstract Number: 569

Sarcopenia, Segmental Muscle Strength and Body Composition in Young Axial Spondylarthritis Patients: Results from MyoSpA Study
Abstract Number: 1398

Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 2710

Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study
Abstract Number: 1920

School Nurse Education for Juvenile Idiopathic Arthritis
Abstract Number: 2124

Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas’ Disease). Is It Possible a Reactivation?
Abstract Number: 313

Screening and Treating Hyperlipidemia in Patient’s on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib
Abstract Number: 2100

Screening for Hepatitis B Surface Antigen and Core Antibody Prior to Administration of Rituximab in Rheumatology Patients
Abstract Number: 2589

Searching the Calcinosis Signature: A Case Control Study Analyzing Limited Systemic Sclerosis Female Patients with and Without Calcinosis, Paired by Disease Duration, Age and Body Mass Index
Abstract Number: 399

Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)
Abstract Number: 380

Seasonal Clustering of Acute Sarcoidosis in South-West Germany and Associations with Particulate Matter Air Pollution
Abstract Number: 398

Seasonal Variation in Idiopathic Inflammatory Myopathies Incidence and Presentation: A Retrospective Study in Beijing and Hong Kong
Abstract Number: 702

Seasonality of Cutaneous and Systemic Flares in Adults and Children in the Einstein Lupus Cohort
Abstract Number: 14

Sec16A Abnormalities Affect the Intracellular Trafficking of HLA-B27 in the Pathogenesis of Axial Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].